Baclofen EP Impurity B(CAS: 1141-23-7)

Baclofen EP Impurity B (CAS: 1141-23-7) is subject to regulatory guidelines such as GHS classification, which categorizes it based on its physical, health, and environmental hazards. It also falls under REACH regulations, which require suppliers to register substances above a certain tonnage threshold. FDA and EPA have specific requirements for the handling, storage, and disposal of this compound. Compliance with these guidelines ensures safe and legal handling of the substance.

In synthesis, alternatives to Baclofen EP Impurity B (CAS: 1141-23-7) may include similar dihydropyridines or other muscle relaxants. Common alternative reagents like 4-chlorophenylacetic acid or other precursor chemicals can be used. However, these alternatives should be evaluated for their effectiveness and compatibility with the specific synthesis process.

The market for Baclofen EP Impurity B (CAS: 1141-23-7) is driven by its role as a byproduct in the synthesis of Baclofen, a muscle relaxant used to treat spasticity. Research trends focus on its pharmacological properties and potential applications. Market trends show a steady demand, but there is ongoing research to explore its use in new drug formulations and therapies.

Waste containing Baclofen EP Impurity B (CAS: 1141-23-7) should be collected in appropriate containers and stored in a secure, designated area. Incineration or professional waste disposal methods should be used to ensure safe destruction. Environmental protection precautions include following local and federal regulations for hazardous waste disposal. Proper documentation and labeling of waste are crucial for compliance and safety.